Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7045MR)

This product GTTS-WQ7045MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7045MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12580MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ5877MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ269MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ6822MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ14728MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ13129MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ15309MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ9849MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW